BCIQ Profiles

Company Profile Report
0331 Finance QTs
BioCentury & Getty Images


March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

Mar 31, 2021 | 11:42 PM GMT

Achilles Therapeutics Inc. (NASDAQ:ACHL) briefly traded above its $18 IPO price before ceding ground in its first day of trading, settling to $16.55 in trading Wednesday. The clinical T cell therapeutics developer raised $175.5 million through the sale of 9.8 million

Read the full 662 word article

How to gain access

Continue reading with a
two-week free trial.